32 research outputs found

    Suitability of a low-cost wearable sensor to assess turning in healthy adults

    Get PDF
    Background: Turning is a complex measure of gait that accounts for over 50 of daily steps. Traditionally, turning has been measured in a research grade laboratory setting, however, there is demand for a low-cost and portable solution to measure turning using wearable technology. This study aimed to determine the suitability of a low-cost inertial sensor-based device (AX6, Axivity) to assess turning, by simultaneously capturing and comparing to a turn algorithm output from a previously validated reference inertial sensor-based device (Opal), in healthy young adults. Methodology: Thirty participants (aged 23.9 ± 4.89 years) completed the following turning protocol wearing the AX6 and reference device: a turn course, a two-minute walk (including 180° turns) and turning in place, alternating 360° turn right and left. Both devices were attached at the lumbar spine, one Opal via a belt, and the AX6 via double sided tape attached directly to the skin. Turning measures included number of turns, average turn duration, angle, velocity, and jerk. Results: Agreement between the outcomes from the AX6 and reference device was good to excellent for all turn characteristics (all ICCs > 0.850) during the turning 360° task. There was good agreement for all turn characteristics (all ICCs > 0.800) during the two-minute walk task, except for moderate agreement for turn angle (ICC 0.683). Agreement for turn outcomes was moderate to good during the turns course (ICCs range; 0.580 to 0.870). Conclusions: A low-cost wearable sensor, AX6, can be a suitable and fit-for-purpose device when used with validated algorithms for assessment of turning outcomes, particularly during continuous turning tasks. Future work needs to determine the suitability and validity of turning in aging and clinical cohorts within low-resource setting

    Children must be protected from the tobacco industry's marketing tactics.

    Get PDF

    IMPACT-Global Hip Fracture Audit: Nosocomial infection, risk prediction and prognostication, minimum reporting standards and global collaborative audit. Lessons from an international multicentre study of 7,090 patients conducted in 14 nations during the COVID-19 pandemic

    Get PDF

    Finishing the euchromatic sequence of the human genome

    Get PDF
    The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

    OPTIMISATION OF CRITICALITY AND BURNUP CALCULATIONS IN MONK®

    Get PDF
    The primary goal of this paper is to increase the efficiency of criticality and burnup calculations in the ANSWERS MONK® Monte Carlo code [1]. Two ways of achieving this goal are investigated as part of the H2020 McSAFE Project: creating a unified energy grid for all materials in the model, and reducing the spread in variances of fluxes for depletable materials using a generated optimised importance map. The average tracking speedup factor across all cycles of all burnup calculations ran using the unified energy grid, at base temperature, was found to be 1.96. For criticality calculations at 400K with runtime Doppler broadening, the unified grid approach gave a total speedup factor of 7.32. This demonstrates the potential importance of this method to reduce the calculation time with models with runtime Doppler broadening. The use of the generated optimised importance map has been demonstrated to significantly reduce the variance in the standard deviations on the fluxes in the fuel pins across two different test cases. If a solution is required in which the standard deviation in none of the fuel pins exceeds 5% it was found that the number of scoring stages required was more than halved, highlighting the potential for the outlined methodology to speedup burnup credit calculations

    OPTIMISATION OF CRITICALITY AND BURNUP CALCULATIONS IN MONK

    No full text
    The primary goal of this paper is to increase the efficiency of criticality and burnup calculations in the ANSWERS MONK® Monte Carlo code [1]. Two ways of achieving this goal are investigated as part of the H2020 McSAFE Project: creating a unified energy grid for all materials in the model, and reducing the spread in variances of fluxes for depletable materials using a generated optimised importance map. The average tracking speedup factor across all cycles of all burnup calculations ran using the unified energy grid, at base temperature, was found to be 1.96. For criticality calculations at 400K with runtime Doppler broadening, the unified grid approach gave a total speedup factor of 7.32. This demonstrates the potential importance of this method to reduce the calculation time with models with runtime Doppler broadening. The use of the generated optimised importance map has been demonstrated to significantly reduce the variance in the standard deviations on the fluxes in the fuel pins across two different test cases. If a solution is required in which the standard deviation in none of the fuel pins exceeds 5% it was found that the number of scoring stages required was more than halved, highlighting the potential for the outlined methodology to speedup burnup credit calculations

    Thigh-length compression stockings and DVT after stroke

    Get PDF
    Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease
    corecore